员工持股计划
Search documents
远东股份: 远东智慧能源股份有限公司2025年第一期员工持股计划管理办法
Zheng Quan Zhi Xing· 2025-06-20 08:42
远东智慧能源股份有限公司 (一)依法合规原则 公司实施员工持股计划,严格按照法律、行政法规的规定履行程序, 真实、准确、完整、及时地实施信息披露。任何人不得利用本员工持股计 划进行内幕交易、操纵证券市场等证券欺诈行为。 (二)自愿参与原则 公司实施员工持股计划遵循公司自主决定,员工自愿参加,公司不以 摊派、强行分配等方式强制员工参加本员工持股计划。 第一章 总则 第一条 为规范远东智慧能源股份有限公司(以下简称"远东股份"或 "公司")2025年第一期员工持股计划(以下简称"员工持股计划"、"本 员工持股计划"或"本计划")的实施,根据《中华人民共和国公司法》( 以下简称"《公司法》")、《中华人民共和国证券法》(以下简称"《证 券法》")、《关于上市公司实施员工持股计划试点的指导意见》(以下简 称"《指导意见》")等相关法律、行政法规、规章、规范性文件和《远东 智慧能源股份有限公司章程》(以下简称"《公司章程》")之规定,特 制定本管理办法。 第二章 员工持股计划的制定 第二条 员工持股计划所遵循的基本原则 (三)风险自担原则 当回避表决。董事会在审议通过本员工持股计划草案后的2个交易日内公告 董事会决议、 ...
富佳股份: 宁波富佳实业股份有限公司第三届监事会第三次会议决议公告
Zheng Quan Zhi Xing· 2025-06-20 08:32
Group 1 - The third meeting of the supervisory board of Ningbo Fujia Industrial Co., Ltd. was held, with all three supervisors present, and the meeting was conducted in accordance with legal and regulatory requirements [1][2]. - The supervisory board approved the adjustment of the 2025 employee stock ownership plan's initial and reserved share distribution, confirming that the adjustment complies with relevant laws and regulations, and is beneficial for the company's sustainable development [1][2]. - The board also approved the reserved share distribution for the 2025 employee stock ownership plan, stating that the decision-making process was legal and effective, and that the qualification of the participants meets the necessary criteria [2]. Group 2 - The voting results for the proposals were 2 in favor, 0 against, and 0 abstentions, with specific supervisors recusing themselves from the vote [2]. - The company emphasized that there is no forced participation in the employee stock ownership plan, ensuring that the implementation of the reserved shares will motivate employees and help retain talent [2].
广博股份: 关于2025年员工持股计划第一次持有人会议决议公告
Zheng Quan Zhi Xing· 2025-06-20 08:21
Core Points - The company held its first meeting for the 2025 Employee Stock Ownership Plan (ESOP) on June 16, 2025, with 102 participants representing 29,914,080 shares, which is 100% of the total shares in the plan [1][2] - The meeting approved the establishment of a management committee for the 2025 ESOP to oversee daily management and represent shareholders [1] - The committee consists of three members, with a term aligned with the duration of the 2025 ESOP [1][3] - The meeting also elected Wu Junjie, Zhong Qi, and Chen Hongya as committee members, with their terms also aligned with the ESOP duration [2][3] - The management committee was authorized to handle matters related to the ESOP, including the processing of shares for disqualified holders and changes in holder status [3][4]
广汽埃安员工持股计划引争议 前五月销量8.9万辆同比降12%
Chang Jiang Shang Bao· 2025-06-20 06:30
随后,广汽埃安曾宣布科创板上市,但一直没有新进展。 员工持股到期,涉及偿还借款本金问题,员工持股计划引发争议。 6月16日,广汽埃安在广汽集团官网发布声明称,近期,广汽埃安监测到网络上有部分自媒体发布关于 广汽埃安员工持股相关的不实信息,进行恶意诋毁和传播,严重误导公众,损害广汽埃安的品牌形象。 对此,公司严正声明,此类言论毫无事实依据,纯属恶意谣言。作为广汽旗下核心自主品牌,广汽埃安 的发展得到了广汽集团全力支持,目前生产经营一切正常。有关广汽埃安员工股权激励计划,目前亦依 法依规处于正常推进中。 6月17日晚间,广汽埃安前总经理古惠南发文称,"近期网传广汽埃安员工持股的信息,其中提到高管退 休后已经收回股权投资款和利息,这与事实不符。我虽然已经退休了,仍然和大家一样履行股改所签订 的协议,没有收回本金,继续如期支付利息"。 长江商报奔腾新闻记者 沈右荣 知名新能源汽车公司广汽埃安员工持股计划引发争议。 6月16日,有传言称,广汽埃安员工当初贷款认购的股权如今估值大幅缩水,从6月底起需开始偿还本 金,若强制清退认购资金,只能收回42%。 广汽埃安混改、员工持股计划及IPO进程开始于2021年。彼时广汽埃安宣 ...
宁波继峰汽车零部件股份有限公司关于2025年员工持股计划非交易过户完成的公告
Shang Hai Zheng Quan Bao· 2025-06-19 19:59
登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码:603997 证券简称:继峰股份 公告编号:2025-042 转债代码:110801 转债简称:继峰定01 宁波继峰汽车零部件股份有限公司 关于2025年员工持股计划 非交易过户完成的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏,并对其内容 的真实性、准确性和完整性依法承担法律责任。 宁波继峰汽车零部件股份有限公司(以下简称"公司")于2025年4月9日和2025年4月28日分别召开了第 五届董事会第十七次会议及2024年年度股东大会,审议通过了《关于公司<2025年员工持股计划(草 案)>及其摘要的议案》《关于公司<2025年员工持股计划管理办法>的议案》等相关议案,具体内容 详见公司在2025年4月10日、2025年4月29日于上海证券交易所网站(http://www.sse.com.cn/)披露的相 关公告。 根据《关于上市公司实施员工持股计划试点的指导意见》《上海证券交易所上市公司自律监管指引第1 号一一规范运作》的要求,现将公司2025年员工持股计划实施进展情况公告如下: 根据参与对象实际认购和最终缴 ...
盈趣科技: 关于2025年员工持股计划非交易过户完成的公告
Zheng Quan Zhi Xing· 2025-06-19 12:56
Core Viewpoint - The company has successfully completed the non-trading transfer of shares under its 2025 Employee Stock Ownership Plan (ESOP), which aims to enhance employee engagement and align their interests with the company's performance [1][6]. Group 1: Employee Stock Ownership Plan Details - The 2025 ESOP was approved during the company's board and shareholder meetings held on March 7, 2025, and March 27, 2025, respectively [1]. - The plan involves the transfer of 12,351,780 shares, representing 1.59% of the company's total share capital, from the company's repurchased shares [4][6]. - The total amount raised from employee contributions to the ESOP is approximately RMB 139.58 million, with 448 employees participating [5]. Group 2: Share Repurchase and Funding - The shares for the ESOP were sourced from the company's repurchased A-shares, with a total of 9,679,297 shares repurchased in 2022 and 4,584,553 shares in 2023 [2][3]. - The total amount spent on share repurchases was approximately RMB 199.99 million in 2022 and RMB 69.92 million in 2023 [2][3]. - As of the last transfer, the company had a total of 22,122,142 shares available for the ESOP, which is 2.85% of the total share capital [4]. Group 3: Plan Structure and Governance - The ESOP has a duration of 60 months, with shares unlocking in three phases based on performance metrics [6]. - The plan does not involve any financial assistance or guarantees from the company to the participants [5]. - Participants in the ESOP will voluntarily waive their voting rights associated with the shares held under the plan [7]. Group 4: Accounting Treatment - The expenses related to the ESOP will be amortized according to relevant accounting standards, impacting the company's net profit during the plan's duration [8]. - The plan is expected to positively influence employee motivation and operational efficiency, although the exact financial impact will be determined by annual audit reports [8].
德生科技:员工持股计划非交易过户完成
news flash· 2025-06-19 11:40
德生科技(002908)公告,公司2025年员工持股计划非交易过户已完成,过户股份数量为174.56万股, 占公司目前总股本4.31亿股的0.40%,过户价格为4.43元/股。本次员工持股计划实际参与认购份额的员 工人数为61人,实际缴纳认购资金总额为773.3万元。公司已在中国证券登记结算有限责任公司深圳分 公司开立了本次员工持股计划专用证券账户,证券账户号码为8.99亿。此次回购股份已处理完成,实际 用途与回购股份方案中的拟定用途不存在差异。 ...
诺唯赞: 诺唯赞关于以集中竞价交易方式回购公司股份的回购报告书
Zheng Quan Zhi Xing· 2025-06-19 10:42
Core Viewpoint - Nanjing Novogene Bioinformatics Technology Co., Ltd. plans to repurchase its shares through centralized bidding, with a total repurchase amount ranging from RMB 5 million to RMB 10 million, aimed at implementing equity incentives or employee stock ownership plans [1][4][6]. Summary by Relevant Sections Repurchase Plan Details - The repurchase amount is set between RMB 5 million and RMB 10 million [1][4]. - The funding source for the repurchase will be the company's own funds [1][4]. - The maximum repurchase price is capped at RMB 30 per share, which does not exceed 150% of the average trading price over the last 30 trading days prior to the board's decision [1][4][6]. - The repurchase will be conducted through the Shanghai Stock Exchange's trading system [1][5]. - The duration for the repurchase is within 12 months from the board's approval date [1][4]. Purpose and Use of Repurchased Shares - The repurchased shares will be used for implementing equity incentives or employee stock ownership plans [1][4][8]. - If the company fails to implement these plans within three years after the repurchase, the unutilized shares will be canceled [1][4][12]. Shareholder and Management Plans - Major shareholders, including the actual controller and board members, have no plans to reduce their holdings in the next three to six months [2][10][11]. - The proposal for the repurchase was initiated by the actual controller and chairman, Mr. Cao Lin, based on confidence in the company's future development [12][13]. Financial Impact and Structure Changes - As of March 31, 2025, the company's total assets were RMB 5.266 billion, with net assets attributable to shareholders at RMB 3.901 billion [8]. - The repurchase amount, if at the upper limit of RMB 10 million, would represent approximately 0.02% of total assets and 0.26% of net assets [8]. - The repurchase is expected to have no significant impact on the company's operations, financial status, or future development [8]. Compliance and Authorization - The repurchase plan has been approved by more than two-thirds of the board members and does not require shareholder meeting approval [3][4]. - The management is authorized to handle all matters related to the repurchase, including adjustments to the plan as necessary [13][14].
明志科技: 远闻(上海)律师事务所关于苏州明志科技股份有限公司差异化分红事项的法律意见书
Zheng Quan Zhi Xing· 2025-06-19 10:01
Core Viewpoint - The legal opinion letter from Yuanwen (Shanghai) Law Firm confirms the legality and compliance of Suzhou Mingzhi Technology Co., Ltd.'s differentiated dividend distribution for the fiscal year 2024, ensuring it aligns with relevant laws and regulations [1][8]. Group 1: Differentiated Dividend Distribution - The differentiated dividend distribution is necessitated by the company's repurchased shares, which do not participate in profit distribution as per the relevant laws and regulations [4][5]. - The company plans to distribute a cash dividend of 4.50 yuan per 10 shares (including tax), excluding the 534,750 shares held in the repurchase account from this distribution [5][6]. - The total number of shares eligible for profit distribution is calculated to be 123,421,322 shares after excluding the repurchased shares from the total share capital of 123,956,072 shares [6][7]. Group 2: Legal Compliance and Verification - The law firm has conducted thorough verification of the legal compliance of the differentiated dividend distribution, ensuring no false records or misleading statements exist [2][3]. - The legal opinion letter serves as a necessary legal document for the company's differentiated dividend distribution and is subject to legal responsibility by the law firm [2][3]. - The law firm emphasizes that it only provides opinions on legal matters related to the differentiated dividend distribution and does not assess accounting or financial aspects [3][4].
成大生物: 中信证券股份有限公司关于辽宁成大生物股份有限公司以集中竞价交易方式回购公司股份的核查意见
Zheng Quan Zhi Xing· 2025-06-19 09:22
中信证券股份有限公司 关于辽宁成大生物股份有限公司 以集中竞价交易方式回购公司股份的核查意见 中信证券股份有限公司(以下简称"保荐机构"或"中信证券")作为辽宁 成大生物股份有限公司(以下简称"成大生物"或"公司")首次公开发行股票 并在科创板上市的持续督导保荐机构,根据《上海证券交易所科创板上市公司自 律监管指引第 1 号——规范运作》《上市公司募集资金监管规则》《上海证券 交易所上市公司自律监管指引第 7 号——回购股份》等有关规定,对公司以集 中竞价交易方式回购股份的事项进行了核查,具体情况如下: 一、回购方案的审议及实施程序 金通过上海证券交易所交易系统以集中竞价交易方式回购公司已发行的部分人 民币普通股(A股)股票。具体内容详见 公司在上海证券交易所网站 (www.sse.com.cn)披露的《辽宁成大生物股份有限公司关于公司董事长提议回 购公司股份的提示性公告》(公告编号:2025-032)。 以集中竞价交易方式回购公司股份方案的议案》。公司全体董事出席会议,表决 结果为9票同意、0票反对、0票弃权,经三分之二以上董事出席的董事会会议决 议通过。根据《上市公司股份回购规则》及《公司章程》之规定,本 ...